Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Aims to achieve CDMO sales of US$ 400 million by 2028
Subscribe To Our Newsletter & Stay Updated
